trivirus specific ctls for ebv, cmv and adenovirus infection

Cell therapyexperimental

Clinical trial activity

1 trials · 12 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Nov 1, 2008 (NCT00711035)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • trivirus specific ctls for ebv, cmv and adenovirus infection

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00711035Phase 1/Phase 2 (Phase 2)Nov 1, 2008Baylor University, Duke University, Harvard University, Methodist Cancer Center, Houston, Texas, National Heart, Lung, and Blood Institute (NHLBI), National Marrow Donor Program, Rutgers University, The EMMES Corporation, University of California, Los Angeles, University of Miami, University of Southern California, University of Texas at Houston
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Baylor UniversityAcademic/Hospital1112008
Duke UniversityAcademic/Hospital1012008
Harvard UniversityAcademic/Hospital1012008
Methodist Cancer Center, Houston, TexasAcademic/Hospital1012008
National Heart, Lung, and Blood Institute (NHLBI)Government1012008
National Marrow Donor ProgramGovernment1012008
Rutgers UniversityAcademic/Hospital1012008
The EMMES CorporationFor profit1012008
University of California, Los AngelesAcademic/Hospital1012008
University of MiamiAcademic/Hospital1012008
University of Southern CaliforniaAcademic/Hospital1012008
University of Texas at HoustonAcademic/Hospital1012008
12 organizations
Page 1 / 1